Is Redcare Pharmacy Stock Finding a Floor?

Shares of Redcare Pharmacy have plummeted approximately 76% since the beginning of May 2025, pushing the equity into a state of extreme technical undervaluation. After hitting a fresh five-year low of just over €30.82 early last week, the stock price attempted its first signs of stabilization on Monday.

A Multifaceted Challenge

The difficult environment for digital health providers stems from several concurrent pressures. On March 23, brick-and-mortar pharmacists in Berlin, Brandenburg, and North Rhine-Westphalia staged demonstrations. Their protests targeted existing fee structures and the increasing competition from online pharmacies, bringing the German pharmacy sector's underlying structural tensions into public view and further eroding investor confidence.

Compounding these external pressures is a revision of the company's own medium-term targets. Management has adjusted its guidance for the adjusted EBITDA margin from "over 8 percent" down to "over 5 percent." For the 2026 fiscal year, the company anticipates revenue growth of between 13 and 15 percent, with an EBITDA margin expected to reach at least 2.5 percent.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Mixed Operational Signals

Redcare's 2025 financial results present a dual narrative. While the company's German prescription (Rx) revenue nearly doubled to €503 million and group sales climbed to €2.94 billion, its gross margin contracted from 22.3% to 21.3%. This decline is a direct consequence of the growing proportion of lower-margin prescription medicines within its sales mix.

The key question for investors is whether the recent Relative Strength Index (RSI) reading of 17 genuinely signals a technical bottom. A clearer picture will emerge on May 6, when Redcare is scheduled to release its first-quarter 2026 results. Notably, Deutsche Bank has maintained a positive assessment of the stock, a stance that contrasts with the prevailing market skepticism.

Ad

Redcare Pharmacy Stock: New Analysis - 31 March

Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Redcare Pharmacy analysis...

NL0012044747 | REDCARE | boerse | 69033819 |